Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.

Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, Barvencik F, Zustin J, Gratz KF, Amling M.

Bone. 2014 Jul;64:222-7. doi: 10.1016/j.bone.2014.04.016. Epub 2014 Apr 24.

PMID:
24769333
[PubMed - in process]
2.

Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.

Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U.

Mol Imaging Biol. 2003 Jan-Feb;5(1):42-8.

PMID:
14499161
[PubMed - indexed for MEDLINE]
3.

68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ.

J Nucl Med. 2007 Apr;48(4):508-18.

PMID:
17401086
[PubMed - indexed for MEDLINE]
Free Article
4.

Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.

Velikyan I, Xu H, Nair M, Hall H.

Nucl Med Biol. 2012 Jul;39(5):628-39. doi: 10.1016/j.nucmedbio.2011.12.010. Epub 2012 Feb 14.

PMID:
22336375
[PubMed - indexed for MEDLINE]
5.

Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.

Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):364-72. doi: 10.1007/s00259-012-2286-6. Epub 2012 Nov 14.

PMID:
23151915
[PubMed - indexed for MEDLINE]
6.

Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography.

Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, Gratz KF, Bastian L.

J Bone Miner Res. 2007 Jan;22(1):158-62.

PMID:
17014386
[PubMed - indexed for MEDLINE]
7.

Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.

Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Araman A, Kanmaz B.

Nucl Med Commun. 2013 Nov;34(11):1084-9. doi: 10.1097/MNM.0b013e328364eaab.

PMID:
23939265
[PubMed - indexed for MEDLINE]
8.

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE.

Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A.

Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10. doi: 10.1007/s00259-010-1512-3.

PMID:
20596866
[PubMed - indexed for MEDLINE]
9.

Tumor localization and biochemical response to cure in tumor-induced osteomalacia.

Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, Gafni RI, Bhattacharyya N, Boyce AM, El-Maouche D, Crespo DO, Sherry R, Chang R, Wodajo FM, Kletter GB, Dwyer A, Collins MT.

J Bone Miner Res. 2013 Jun;28(6):1386-98. doi: 10.1002/jbmr.1881.

PMID:
23362135
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

68Ga-Labeled (1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid)-1-NaI3-octreotide.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 May 12 [updated 2009 Jun 05].

PMID:
20641226
[PubMed]
Books & Documents
11.

68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.

Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, Montini GC, Mattioli S, Grassetto G, Al-Nahhas A, Franchi R, Fanti S.

Nucl Med Commun. 2009 Apr;30(4):281-6. doi: 10.1097/MNM.0b013e32832999c1.

PMID:
19247211
[PubMed - indexed for MEDLINE]
12.

Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.

Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM, Baum RP.

Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):501-11. doi: 10.1007/s00259-011-2003-x. Epub 2011 Dec 20.

PMID:
22183108
[PubMed - indexed for MEDLINE]
13.

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.

J Nucl Med. 2009 Sep;50(9):1427-34. doi: 10.2967/jnumed.108.053421. Epub 2009 Aug 18.

PMID:
19690033
[PubMed - indexed for MEDLINE]
Free Article
14.

Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.

Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B.

Nucl Med Commun. 2013 Aug;34(8):727-32. doi: 10.1097/MNM.0b013e328362cca6.

PMID:
23728519
[PubMed - indexed for MEDLINE]
15.

Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in Localization of Tumor Causing Oncogenic Osteomalacia.

Agrawal K, Bhadada S, Mittal BR, Shukla J, Sood A, Bhattacharya A, Bhansali A.

Clin Nucl Med. 2014 Jul 3. [Epub ahead of print]

PMID:
24999675
[PubMed - as supplied by publisher]
16.

Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.

Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, Dudczak R, Virgolini I.

Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1144-51. Epub 2005 May 21.

PMID:
15909194
[PubMed - indexed for MEDLINE]
17.

Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.

Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, Kranewitter C, Warwitz B, Waitz D, Kendler D, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2011 May;38(5):865-73. doi: 10.1007/s00259-010-1720-x. Epub 2011 Jan 29.

PMID:
21279352
[PubMed - indexed for MEDLINE]
18.

Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT.

Clifton-Bligh RJ, Hofman MS, Duncan E, Sim IeW, Darnell D, Clarkson A, Wong T, Walsh JP, Gill AJ, Ebeling PR, Hicks RJ.

J Clin Endocrinol Metab. 2013 Feb;98(2):687-94. doi: 10.1210/jc.2012-3642. Epub 2013 Jan 7.

PMID:
23295468
[PubMed - indexed for MEDLINE]
19.

111In/68Ga-Labeled DOTA-conjugated cyclo[γ-d-Glu-Ala-Tyr-d-Lys]-Trp-Met-Asp-Phe-NH2 (cyclo-MG1), a minigastrin analog.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 May 17 [updated 2012 Jul 12].

PMID:
22787691
[PubMed]
Books & Documents
20.

PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.

Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Mäcke HR, Hofmann M, Debus J, Haberkorn U.

J Nucl Med. 2001 Jul;42(7):1053-6.

PMID:
11438627
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk